Fund+ – Investing in Life Sciences
V-Bio Ventures - Capital for Life Sciences
ABOUT – Tech Lane
Description: Rapid viral control in a world that needs it. ExeVir develops single-domain antibody-based therapies that help patients ward off viral infections. Our lead drug candidate is in accelerated development as a COVID-19 therapeutic.
ExeVir’s unique platform uses heavy chain-only (VHH) antibody fragments derived from camelid single-domain antibodies. The small size and flexibility of the VHH antibody fragments means they can be used like building blocks – linked together into a single drug molecule capable of addressing multiple targets on a bacterial cell or viral particle. These multi-specific antibodies are particularly helpful in tackling fast-moving mutations, giving ExeVir therapies an advantage against disease variants and subtyp
Thanks to the short throughput time needed to generate new drug candidates, ExeVir’s modular platform can be used to respond rapidly to existing and future threats to public health. The resulting therapeutics are stable, cost-effective, and easy to produce, facilitating global access to protection and treatment.
ExeVir collaborates closely Belgium’s leading life sciences research institute VIB, developing new VHH antibodies together with the laboratories of Prof. Xavier Saelens and Prof. Nico Callewaert (VIB – Ghent University).
Fund+ – Investing in Life Sciences
V-Bio Ventures - Capital for Life Sciences
ABOUT – Tech Lane